Email not displaying correctly? View it in your browser


Expansion of DNDi's portfolio
to paediatric HIV and helminth
infections


Interview of Bernard Pécoul,Interview of Bernard Pecoul
DNDi Executive Director
DNDi launches new drug development programme to address treatment needs of children with HIV/AIDS
Millions of children are infected with HIV/AIDS in low- and middle-income countries without adapted treatments and their specific needs are insufficiently taken into consideration in the international HIV research and development agenda.
Read more

Interview of LallementInterview of Marc Lallemant, Head of DNDi HIV programme

Innovative partnership advances novel drug candidate to combat sleeping  sickness

DNDi, Anacor Pharmaceuticals, and SCYNEXIS Inc. announced the successful completion of pre-clinical studies for the first new oral candidate, SCYX-7158, discovered to combat sleeping sickness.
Read more

Publication of these results in PLoS NTDs
Read more

Major progress of clinical activities on Chagas disease

DNDi starts recruitment of patients for three new studies on diagnose and treatment of Chagas disease in Argentina and Bolivia.
Read more
 
DNDi expands its activities to tackle urgent unmet needs for neglected patients in the field of helminth infections
5.8 million USD granted to DNDi by The Bill & Melinda Gates Foundation to develop flubendazole as a safe, highly efficacious and field-usable macrofilaricidable drug candidate for onchocerciasis-Loa loa co-infections.
Read more

Innovative IP agreement between Sanofi and DNDi

This agreement will allow for new molecular scaffolds to be researched under non-exclusive sub-licensable licenses.
Read more

Eliminate the neglect: U.S. support needed to expand assault on neglected diseases

Open-Editorial by Bernard Pécoul, DNDand Peter Hotez, Sabin Vaccine Institute.
Read more